CDDO-EA
CAS: 932730-51-3
Rif. 3D-HMB73051
1mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione |
Informazioni sul prodotto
CDDO-EA is a synthetic compound that is being studied for its potential as an anti-cancer therapy. This agent has shown to have growth factor-β1 response elements and can be used as an experimental model for proton irradiation. CDDO-EA has been shown to work by inhibiting the production of reactive oxygen species that are produced in response to oxidative injury, which may lead to cancer. CDDO-EA also promotes the development of the M2 phenotype, which suppresses tumor growth and causes myeloid-derived suppressors (MDS) cells to develop in a tumor microenvironment. These cells produce cytokines that promote an anti-tumor immune response.